Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities

Recruiting now

Conditions studied: Information Seeking Behavior

In brief

(a) To explore the feasibility and utility of implementing broad preemptive pharmacogenomic result delivery in the inpatient setting across multiple institutions specifically with the goal of incorporating minority-specific pharmacogenomic information; (b) To determine whether clinical outcomes for the drug warfarin are improved in African Americans through the availability of pharmacogenomics-based dosing guidance at the point-of-care.

Key facts

Study ID

NCT03225820

Run by

University of Chicago

People needed

1000

Starts

2017-11-09

Expected to finish

2028-03-01

Last updated by the study team

2026-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be at least 18 years of age.
• Patients must self-identify as African American

You may not qualify if…

• Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
• Patients with known active or prior leukemia.
• Inability to understand and give informed consent to participate.
• For patients being recruited to the warfarin sub-study, those with a glomerular filtration rate or creatinine clearance <30 mL/min34.

Where it is running

• The University of Illinois at Chicago — Chicago, Illinois, United States (enrolling)
• Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.